Short Interest in Veru Inc. (NASDAQ:VERU) Grows By 19.2%

Veru Inc. (NASDAQ:VERU) saw a large increase in short interest in January. As of January 15th, there was short interest totaling 735,150 shares, an increase of 19.2% from the December 31st total of 616,770 shares. Based on an average daily volume of 127,880 shares, the short-interest ratio is currently 5.7 days. Currently, 5.4% of the shares of the stock are sold short. Currently, 5.4% of the shares of the stock are sold short. Based on an average daily volume of 127,880 shares, the short-interest ratio is currently 5.7 days.

Institutional Investors Weigh In On Veru

Institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd acquired a new position in shares of Veru in the second quarter worth $36,000. Northwestern Mutual Wealth Management Co. purchased a new position in Veru in the third quarter valued at about $38,000. Allworth Financial LP acquired a new position in Veru in the 2nd quarter worth about $45,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Veru during the 3rd quarter worth about $47,000. Finally, XTX Topco Ltd acquired a new stake in shares of Veru during the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a research note on Saturday. Canaccord Genuity Group started coverage on Veru in a report on Thursday, December 18th. They issued a “buy” rating and a $25.00 price target on the stock. Oppenheimer reissued an “outperform” rating on shares of Veru in a research note on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.50.

Veru Trading Down 0.4%

Shares of VERU stock opened at $2.56 on Wednesday. The company has a market capitalization of $41.09 million, a price-to-earnings ratio of -1.16 and a beta of -1.42. Veru has a 1-year low of $2.10 and a 1-year high of $7.40. The stock’s fifty day simple moving average is $2.44 and its 200-day simple moving average is $3.23.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Wednesday, December 17th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.18. During the same period last year, the business earned ($0.28) EPS. On average, sell-side analysts predict that Veru will post -0.22 EPS for the current year.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.